We also included an in-house LUAD patient cohort (n = 52) registered in the National Cancer Center and performed immunohistochemical (IHC) scores of patients’ paraffin samples to evaluate CFP1 expression (Fig. 1h), and the survival analysis showed that patients with higher CFP1 expression had worse OS (Fig. 1i). This evidence concerns the gene CXXC1 and cancer.